Rapid-acting insulin formulation comprising a substituted anionic compound
A composition in aqueous solution includes insulin and at least one substituted anionic compound chosen from substituted anionic compounds consisting of a backbone formed from a discrete number u of between 1 and 8 (1≤u≤8) of identical or different saccharide units, linked via identical or different glycoside bonds, the saccharide units being chosen from the group consisting of hexoses, in cyclic form or in open reduced form, said compound comprising partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. A pharmaceutical formulation including the composition is also set forth.
1. A rapid acting insulin lispro pharmaceutical composition suitable for injection and having a pH of 7.4±0.4, comprising:
an insulin lispro in hexameric form; wherein the insulin has a concentration between 100 to 200 IU/mL;
a polyanionic compound in a concentration between 10 and 30 mM, wherein the polyanionic compound is citric acid or the Na + , K + , Ca 2+ or Mg 2+ salt thereof;
a preservative;
a tonicity agent;
the insulin pharmaceutical composition having a circular dichroism signal at 251 nm at or below −300 deg cm 2 dmol −1 .
2. The rapid acting insulin lispro pharmaceutical composition of claim 1 , wherein the pharmaceutical composition does not include EDTA.
3. The rapid acting insulin lispro pharmaceutical composition of claim 1 , wherein the tonicity agent is selected from the group consisting of glycerol, sodium chloride (NaCl), mannitol and glycine.
4. The rapid acting insulin lispro pharmaceutical composition of claim 3 , wherein the tonicity agent is sodium chloride.
5. The rapid acting insulin lispro pharmaceutical composition of claim 4 , further comprising zinc salts.
6. The rapid acting insulin lispro pharmaceutical composition of claim 1 , wherein the preservative is m-cresol.
7. The rapid acting insulin lispro pharmaceutical composition of claim 5 , further comprising a surfactant.